PO.ET07.02 · 实验与分子治疗
Pharmacogenomics and Translational Biomarkers for Precision Cancer Therapy
- 3133 3133 A pharmacogenetic interaction analysis of second-line chemotherapy with bevacizumab in metastatic colorectal cancer patients: Results from the randomized BEBYP trial Arianna Bandini, Paola Orlandi, Marco Scalese, Gianluca Masi, Federica Marmorino, Chiara Cremolini, Guido Bocci
-
-
- 3137 3137 Partial alternative splicing in carriers of DPYD rs75017182 explains modest association with severe 5-FU toxicity to 5-FU Lauryn Allyn Hahn, Ryan Schwartz, Hannah Marie Krause, Lulu Jiang, Brianna Bembenek, Kelly Bouchonville, Steven M. Offer
-
-
-
-
- 3142 3142 Genomic determinants of response to the Wnt/Beta-catenin condensate modulator DPTX3186 in gastric cancer PDX models and implications for clinical development Francis Carpenter, Kip West, Doug Baumann, Adam Talbot, Thomas Durand-Reville, Karl Hsu, Ann Boija, Isaac Klein
- 3143 3143 Co-targeting of two distinct androgen receptor-regulated signaling pathways as a therapeutic approach in prostate cancer Min-Yu Ko, Rachid Safi, Suzanne E. Wardell, Paige Watkinson, Isabel Jones, Brianna Richardson, John D. Norris, Donald P. McDonnell
-
-
-
-
- 3148 3148 Human blood micronucleated reticulocytes: Application as a pharmacodynamic biomarker for DNA double strand breaks in oncology drug development Jeffrey C. Bemis, Colette Baxter, Gillian Langford, Timothy A. Yap, Susanna Varkey Ulahannan, Nehal Lakhani, Babar Bashir, Kathleen N. Moore, Payal Shah, Svetlana Avlasevich, Dorothea Torous, Stephen Dertinger
- 3149 3149 Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043 Colette L. Baxter, Timothy A. Yap, Susanna V. Ulahannan, Nehal Lakhani, Minal Barve, Erika P. Hamilton, Babar Bashir, Helen M. R. Robinson, Jayesh B. Majithiya, Paula Costales, Sarah V. Holt, Samantha C. Skelton, Marina Roy-Luzarraga, Jeff C. Bemis, Dorothea Torous, Svetlana Avlasevich, Susana Barriga, Bryony Harrop, Gillian A. Langford, Ian Smith, Graeme C. M. Smith
- 3150 3150 InVEST44™ is a cost-effective in vitro safety panel that identifies off-target effects in early-stage drug discovery Julian R. Wooltorton, Afsara Ahona, Nicole Barbacane, Alex D'Andrea, Justin Lansberry, Cindy Lay, Paige Miller, John Ries, Jamin Steffen, Patricia Valentine
- 3151 3151 High-throughput high-plex proteomic profiling of hepatocyte toxicity to oncologic drug compounds: A platform for toxicity assessment, immune risk prediction, and drug development acceleration Nicole Paul, Alyssa Rosenbloom, Nathaniel Robichaud, Kiran Edwardson, Nathan Chang, Narges Rashidi, Milad Dagher
-
- 3153 3153 An integrated in vitro profiling platform for the simultaneous assessment of anti cancer efficacy and multi organ toxicity Xia Tu, Hao Wen, Dawei Yan, Jingna Ren, Qin Guo, Peichuan Zhang, Haiheng Dong
-
- 3155 3155 Pharmacokinetic/pharmacodynamic correlation and biodistribution of Re (CO)3-phenformin compared with phenformin in murine PDAC model following equimolar intravenous dosing Amir Mohammad Gholizadeh, Fatima Dagher, Mikayla Skillman, Airong Li, Chun Li, Diana S-L Chow
-
- 3157 3157 Pharmacokinetic/pharmacodynamic correlation and biodistribution of paclitaxel and cyclopamine from M-CPA/PTX in HCC mice following multiple dosing Emanuel R. Baltrip, Lu Dai, Qiu-Xu Teng, Defeng Deng, Guodong Zhang, Chun Li, Diana S.-L. Chow
- 3158 3158 Pharmacokinetic and biodistribution evaluation of nebivolol and dasatinib in the 4T1 triple-negative breast cancer model: Implications for drug-drug interaction Airong Li, Mikayla Skillman, Junhyoung Park, Fatima Dagher, Amir M. Gholizadeh, Emanuel Baltrip, Meghana Trivedi, Benny A. Kaipparettu, Diana S.-L. Chow
-
-
